Yatharth Hospital & Trauma Care Services Limited's promoter Dr. Kapil Kumar has released pledge on 25,75,000 equity shares of the company on December 5 and 9, 2025. The disclosure was made to the stock exchanges under Regulation 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 on December 10, 2025.

Pledge Release Details

The pledge release transaction involved 25,75,000 equity shares, representing 2.67% of the company's total share capital. The pledged shares were released from Jio Finance Ltd and IFL Capital Services.

Impact on Promoter Holdings

Following the pledge release, Dr. Kapil Kumar's shareholding structure has been modified significantly. His total promoter holding in the company remains unchanged at 1,21,24,386 shares, constituting 12.62% of the total share capital.

Regulatory Compliance

The disclosure was submitted by Dr. Kapil Kumar in his capacity as Managing Director and Promoter of the company, holding DIN 01818736. The communication was addressed to both National Stock Exchange of India Limited and BSE Limited, where the company's shares are listed under the symbol YATHARTH with scrip code 543950.

The pledge release represents a significant reduction in the promoter's encumbered shareholding, decreasing from 8.85% to 6.18% of the total share capital. This transaction demonstrates the promoter's commitment to reducing leverage and improving the overall shareholding structure of the healthcare company.

Yatharth Hospital and Trauma Care Services Limited has reported robust financial performance for the second quarter of fiscal year 2026, with significant growth in revenue and operational expansion. The company's strategic initiatives and focus on super-specialty care have driven its performance to new heights.

Financial Highlights

• Revenue reached INR 2,794.00 million, marking a 28% year-over-year increase and an 8% quarter-over-quarter growth.
• EBITDA stood at a record INR 645.00 million, up by 18% year-over-year.
• Adjusted EBITDA, excluding initial losses from newly operationalized facilities, was INR 737.00 million, representing a 35% year-over-year increase.
• Adjusted EBITDA margin remained healthy at 26.70%.
• Adjusted profit after tax grew by 63% year-over-year.

Operational Achievements

• The company added 700 new beds with the commencement of operations at New Delhi and Faridabad facilities.
• Overall occupancy remained strong at 66% despite significant capacity addition.
• Consolidated ARPOB (Average Revenue Per Occupied Bed) increased to INR 32,015.00 in Q2 FY26.
• Mature hospitals, including Noida, Greater Noida, and Noida Extension, achieved a 9% year-over-year ARPOB growth.
• Newer hospitals registered an impressive 19% year-over-year ARPOB growth.

Strategic Developments

1. Expansion: Yatharth Hospital operationalized its Model Town Hospital in New Delhi and Faridabad Sector 20 Hospital, adding 300 and 400 beds respectively.

2. Acquisition: The company acquired Shantived Hospital in Agra, with an expanded capacity of 250 beds, expected to contribute from Q4 FY26.

3. Credit Rating Upgrade: CRISIL upgraded the company's credit rating to CRISIL A/Stable, reflecting strong business prospects.

4. Regulatory Milestone: Income tax authorities unfroze the provisionally attached properties and fixed assets of the company, restoring full financial flexibility for expansion initiatives.

5. Governance Enhancement: Appointed Mr. Ramesh Krishnan as Independent Director and MSKA & Associates as Statutory Auditor, reinforcing transparency and governance standards.

6. Medical Value Travel: Established representative offices in Baghdad and Tashkent, and expanded into Cameroon through institutional and private partnerships.

Outlook

Yatharth Hospital remains optimistic about sustaining its growth trajectory. The company's focus areas include:

• Expanding footprint across North India
• Optimizing existing clinical infrastructure
• Enhancing clinical excellence to drive higher ARPOB
• Capitalizing on emerging sector opportunities

The management expects the newly operationalized facilities in Delhi and Faridabad to achieve EBITDA breakeven within 15-17 months. With a strong net cash position of INR 3,692.00 million, the company is well-positioned to capitalize on future growth opportunities.

Yatharth Tyagi, Whole-Time Director, commented, "This quarter marks a significant phase of operational and strategic progress for Yatharth Hospital, delivering industry-leading performance with the highest ever revenue and EBITDA."

As Yatharth Hospital continues to expand its presence in key markets and enhance its super-specialty offerings, it appears well-positioned for sustained growth in the coming quarters.